HBIO vs HIND
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HBIO exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 93.5%. While the company maintains a healthy gross margin (57.67%) and a positive operating margin (14.01%), these are completely offset by a devastating net profit margin of -65.51%. High leverage (Debt/Equity of 3.22) and negative revenue growth further compound the risk, suggesting the company is struggling to scale or maintain its market position despite a low Price-to-Sales valuation.
Vyome Holdings (HIND) presents a high-risk profile characterized by a catastrophic collapse in share price (-96.1% over 1 year) and severe operational inefficiency. While the Piotroski F-Score of 5/9 suggests a 'stable' baseline in terms of basic financial structure, this is overshadowed by an operating margin of -3707.35% and a massive earnings miss of -2736.4%. The company is trading at an unsustainable Price/Sales ratio of 48.08 despite revenue declining by 40.5% YoY, indicating a complete disconnect between valuation and fundamental performance.
Compare Another Pair
Related Comparisons
HBIO vs HIND: Head-to-Head Comparison
This page compares Harvard Bioscience, Inc. (HBIO) and Vyome Holdings, Inc. (HIND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.